Multiple Sclerosis Clinical Trial
— BIPAMS-BrainOfficial title:
BIPAMS-Brain:Examining the Neural Effects of a Behavioral Intervention for Physical Activity in Multiple Sclerosis
Verified date | September 2021 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multiple sclerosis [MS] is a prevalent neurological disease that is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the United States. This disease results in the progressive loss of walking mobility and substantial worsening of cognition, symptoms, and quality of life over time. There is evidence that physical activity is beneficially associated with aerobic fitness and brain structure and function in persons with MS. Nevertheless, this population is strikingly sedentary and physically inactive. This highlights a vital opportunity to improve aerobic fitness and brain health by developing behavioral interventions that increase physical activity. To that end, this project is a Phase-II randomized control trial for examining the efficacy of a behavioral intervention that is based on social-cognitive theory and delivered through the Internet for increasing physical activity and, secondarily, improving aerobic fitness and brain structure and function in persons with MS.
Status | Completed |
Enrollment | 24 |
Est. completion date | November 3, 2021 |
Est. primary completion date | November 3, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - diagnosis of multiple sclerosis - relapse free in the last 30 days - being non-active defined as not engaging in regular activity (30 minutes accumulated per day) on more than 2 days of the week during the previous 6 months - ambulate without assistance - low risk for contraindications for MRI Exclusion Criteria: - moderate or high risk for undertaking strenuous or maximal exercise |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Minutes of moderate to vigorous physical activity - Baseline | Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days. These activity monitors measure how frequently and how much an individual moves. | Assessment will be conducted before the intervention | |
Primary | Minutes of moderate to vigorous physical activity - Post intervention | Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days. These activity monitors measure how frequently and how much an individual moves. | Assessment will be conducted immediately after the intervention | |
Secondary | cardiorespiratory fitness; oxygen consumption during exercise - baseline | A graded exercise test on a treadmill. Participants will walk at a quick pace on the treadmill and the incline will increase every 2 minutes until the participant is no longer able to keep pace with the treadmill. | Assessment will be conducted before the intervention | |
Secondary | cardiorespiratory fitness; oxygen consumption during exercise - post intervention | A graded exercise test on a treadmill. Participants will walk at a quick pace on the treadmill and the incline will increase every 2 minutes until the participant is no longer able to keep pace with the treadmill. | Assessment will be conducted immediately after the intervention | |
Secondary | distance walked - baseline | The six-minute walk test will be used to measure walking endurance. The test involves walking for 6 minutes without stopping. | Assessment will be conducted before the intervention | |
Secondary | distance walked - post-intervention | The six-minute walk test will be used to measure walking endurance. The test involves walking for 6 minutes without stopping. | Assessment will be conducted immediately after the intervention | |
Secondary | information processing speed; cognitive function - baseline | The symbol digit modalities test will be used to measure information processing speed. The test involves matching numbers to symbols. | Assessment will be conducted before the intervention | |
Secondary | information processing speed; cognitive function - post intervention | The symbol digit modalities test will be used to measure information processing speed. The test involves matching numbers to symbols. | Assessment will be conducted immediately after the intervention | |
Secondary | volume of subcortical grey matter brain structures - baseline | An MRI will be conducted to measure brain structure. | Assessment will be conducted before the intervention | |
Secondary | volume of subcortical grey matter brain structures - post intervention | An MRI will be conducted to measure brain structure. | Assessment will be conducted immediately after the intervention | |
Secondary | resting state functional brain connectivity - baseline | An MRI will be conducted to measure brain function. | Assessment will be conducted before the intervention | |
Secondary | resting state functional brain connectivity - post intervention | An MRI will be conducted to measure brain function. | Assessment will be conducted immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|